In PNH and aHUS, it will compete with Soliris and Ultomiris, but it could become the first treatment for C3G and IMN if approved. While PNH and aHUS are rare diseases, ...

China has become the first country in the world to approve Roche’s anti-complement C5 antibody crovalimab, the only treatment for the rare disorder paroxysmal nocturnal haemoglobinuria (PNH ...